🔴 Chimeric Therapeutics is trading 20% down

Chimeric Therapeutics is trading 20% down at A$0.00, with no clear company-specific catalyst identified for the September 29, 2026 move.

• The latest major development was the August 19 halt to enrollment and dosing in the CHM-2101 trial after dose-limiting toxicities; this predates the move.
• Recent information notes new shares issued from converted securities, but does not link the issuance to the decline.
• The supplied market context shows no same-direction index move large enough to explain the decline.